Literature DB >> 32173028

New genetic predictors for abacavir tolerance in HLA-B*57:01 positive individuals.

Rebecca Pavlos1, Pooja Deshpande2, Abha Chopra3, Shay Leary3, Kaija Strautins3, David Nolan4, Daren Thorborn5, Mark Shaefer6, Andri Rauch7, David Dunn3, Julio Montaner8, Anita Rachlis9, Coral-Ann Almeida10, Linda Choo3, Ian James3, Alec J Redwood11, Yueran Li12, Silvana Gaudieri13, Simon A Mallal14, Elizabeth J Phillips15.   

Abstract

Abacavir hypersensitivity syndrome (ABC HSS) is strongly associated with carriage of human leukocyte antigen (HLA)-B*57:01, which has a 100% negative predictive value for the development of ABC HSS. However, 45% of individuals who carry HLA-B*57:01 can tolerate ABC. We investigated immune and non-immune related genes in ABC HSS (n = 95) and ABC tolerant (n = 43) HLA-B*57:01 + patients to determine other factors required for the development of ABC HSS. Assignment of phenotype showed that ABC HSS subjects were significantly less likely than tolerants to carry only ERAP1 hypoactive trimming allotypes (p = 0.02). An altered self-peptide repertoire model by which abacavir activates T cells is in keeping with observation that endoplasmic reticulum aminopeptidase 1 (ERAP1) allotypes that favour efficient peptide trimming are more common in ABC HSS patients compared to patients who tolerate ABC. Independently, non-specific immune activation via soluble cluster of differentiation antigen 14 (sCD14) may also influence susceptibility to ABC HSS.
Copyright © 2020 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Abacavir hypersensitivity syndrome; Endoplasmic reticulum aminopeptidase 1; Human leukocyte antigen

Mesh:

Substances:

Year:  2020        PMID: 32173028      PMCID: PMC7266722          DOI: 10.1016/j.humimm.2020.02.011

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  22 in total

1.  Immune self-reactivity triggered by drug-modified HLA-peptide repertoire.

Authors:  Patricia T Illing; Julian P Vivian; Nadine L Dudek; Lyudmila Kostenko; Zhenjun Chen; Mandvi Bharadwaj; John J Miles; Lars Kjer-Nielsen; Stephanie Gras; Nicholas A Williamson; Scott R Burrows; Anthony W Purcell; Jamie Rossjohn; James McCluskey
Journal:  Nature       Date:  2012-06-28       Impact factor: 49.962

2.  Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection.

Authors:  Peter W Hunt; Elizabeth Sinclair; Benigno Rodriguez; Carey Shive; Brian Clagett; Nicholas Funderburg; Janet Robinson; Yong Huang; Lorrie Epling; Jeffrey N Martin; Steven G Deeks; Curtis L Meinert; Mark L Van Natta; Douglas A Jabs; Michael M Lederman
Journal:  J Infect Dis       Date:  2014-04-21       Impact factor: 5.226

3.  Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.

Authors:  S Mallal; D Nolan; C Witt; G Masel; A M Martin; C Moore; D Sayer; A Castley; C Mamotte; D Maxwell; I James; F T Christiansen
Journal:  Lancet       Date:  2002-03-02       Impact factor: 79.321

4.  Clinical and immunogenetic correlates of abacavir hypersensitivity.

Authors:  Elizabeth J Phillips; Gavin A Wong; Rupert Kaul; Kamnoosh Shahabi; David A Nolan; Sandra R Knowles; Annalise M Martin; Simon A Mallal; Neil H Shear
Journal:  AIDS       Date:  2005-06-10       Impact factor: 4.177

5.  Plasma levels of soluble CD14 independently predict mortality in HIV infection.

Authors:  Netanya G Sandler; Handan Wand; Annelys Roque; Matthew Law; Martha C Nason; Daniel E Nixon; Court Pedersen; Kiat Ruxrungtham; Sharon R Lewin; Sean Emery; James D Neaton; Jason M Brenchley; Steven G Deeks; Irini Sereti; Daniel C Douek
Journal:  J Infect Dis       Date:  2011-01-20       Impact factor: 5.226

6.  High-Density SNP genotyping defines 17 distinct haplotypes of the TNF block in the Caucasian population: implications for haplotype tagging.

Authors:  Richard J N Allcock; Lydia Windsor; Ivo G Gut; Ramon Kucharzak; Laetitia Sobre; Doris Lechner; Jean-Guillaume Garnier; Svetlana Baltic; Frank T Christiansen; Patricia Price
Journal:  Hum Mutat       Date:  2004-12       Impact factor: 4.878

7.  Naturally occurring ERAP1 haplotypes encode functionally distinct alleles with fine substrate specificity.

Authors:  Emma Reeves; Christopher J Edwards; Tim Elliott; Edward James
Journal:  J Immunol       Date:  2013-06-03       Impact factor: 5.422

8.  Functional Interaction of the Ankylosing Spondylitis-Associated Endoplasmic Reticulum Aminopeptidase 2 With the HLA-B*27 Peptidome in Human Cells.

Authors:  Adrian Martín-Esteban; Pablo Guasp; Eilon Barnea; Arie Admon; José A López de Castro
Journal:  Arthritis Rheumatol       Date:  2016-10       Impact factor: 10.995

9.  HLA-B*5701 screening for hypersensitivity to abacavir.

Authors:  Simon Mallal; Elizabeth Phillips; Giampiero Carosi; Jean-Michel Molina; Cassy Workman; Janez Tomazic; Eva Jägel-Guedes; Sorin Rugina; Oleg Kozyrev; Juan Flores Cid; Phillip Hay; David Nolan; Sara Hughes; Arlene Hughes; Susanna Ryan; Nicholas Fitch; Daren Thorborn; Alastair Benbow
Journal:  N Engl J Med       Date:  2008-02-07       Impact factor: 91.245

10.  Functionally distinct ERAP1 and ERAP2 are a hallmark of HLA-A29-(Birdshot) Uveitis.

Authors:  Jonas J W Kuiper; Jessica van Setten; Matthew Devall; Mircea Cretu-Stancu; Sanne Hiddingh; Roel A Ophoff; Tom O A R Missotten; Mirjam van Velthoven; Anneke I Den Hollander; Carel B Hoyng; Edward James; Emma Reeves; Miguel Cordero-Coma; Alejandro Fonollosa; Alfredo Adán; Javier Martín; Bobby P C Koeleman; Joke H de Boer; Sara L Pulit; Ana Márquez; Timothy R D J Radstake
Journal:  Hum Mol Genet       Date:  2018-12-15       Impact factor: 6.150

View more
  7 in total

Review 1.  Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction.

Authors:  Antonio Segovia-Zafra; Daniel E Di Zeo-Sánchez; Carlos López-Gómez; Zeus Pérez-Valdés; Eduardo García-Fuentes; Raúl J Andrade; M Isabel Lucena; Marina Villanueva-Paz
Journal:  Acta Pharm Sin B       Date:  2021-11-18       Impact factor: 11.413

2.  Delabeling Delayed Drug Hypersensitivity: How Far Can You Safely Go?

Authors:  Rannakoe J Lehloenya; Jonny G Peter; Ana Copascu; Jason A Trubiano; Elizabeth J Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2020-10

Review 3.  Role of pharmacogenomics in T-cell hypersensitivity drug reactions.

Authors:  Rebecca J Hertzman; Pooja Deshpande; Andrew Gibson; Elizabeth J Phillips
Journal:  Curr Opin Allergy Clin Immunol       Date:  2021-08-01

Review 4.  Genomic Risk Factors Driving Immune-Mediated Delayed Drug Hypersensitivity Reactions.

Authors:  Yueran Li; Pooja Deshpande; Rebecca J Hertzman; Amy M Palubinsky; Andrew Gibson; Elizabeth J Phillips
Journal:  Front Genet       Date:  2021-04-16       Impact factor: 4.599

5.  Abacavir inhibits but does not cause self-reactivity to HLA-B*57:01-restricted EBV specific T cell receptors.

Authors:  Anuradha Sooda; Francois Rwandamuriye; Celestine N Wanjalla; Lichen Jing; David M Koelle; Bjoern Peters; Shay Leary; Abha Chopra; Michael A Calderwood; Simon A Mallal; Rebecca Pavlos; Mark Watson; Elizabeth J Phillips; Alec J Redwood
Journal:  Commun Biol       Date:  2022-02-16

Review 6.  Immunopharmacogenomics: Mechanisms of HLA-Associated Drug Reactions.

Authors:  Pooja Deshpande; Rebecca J Hertzman; Amy M Palubinsky; Jason B Giles; Jason H Karnes; Andrew Gibson; Elizabeth J Phillips
Journal:  Clin Pharmacol Ther       Date:  2021-07-17       Impact factor: 6.875

7.  Proteomic Profiling and T Cell Receptor Usage of Abacavir Susceptible Subjects.

Authors:  Eline Gall; Florian Stieglitz; Andreas Pich; Georg Martin Norbert Behrens; Joachim Kuhn; Rainer Blasczyk; Funmilola Josephine Haukamp; Christina Bade-Döding
Journal:  Biomedicines       Date:  2022-03-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.